BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 34498153)

  • 1. Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer.
    Sukumar JS; Quiroga D; Kassem M; Grimm M; Shinde NV; Appiah L; Palettas M; Stephens J; Gatti-Mays ME; Pariser A; Cherian M; Stover DG; Williams N; Van Deusen J; Wesolowski R; Lustberg M; Ramaswamy B; Sardesai S
    Breast Cancer Res Treat; 2021 Nov; 190(2):183-188. PubMed ID: 34498153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
    Bui KT; Willson ML; Goel S; Beith J; Goodwin A
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Goel S; Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.
    Ozaki Y; Tanabe Y; Tamura N; Ogura T; Kondoh C; Miura Y; Yoshimura K; Kawabata H; Takano T
    Breast Cancer; 2018 May; 25(3):343-349. PubMed ID: 29357022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.
    Bernhard J; Luo W; Ribi K; Colleoni M; Burstein HJ; Tondini C; Pinotti G; Spazzapan S; Ruhstaller T; Puglisi F; Pavesi L; Parmar V; Regan MM; Pagani O; Fleming GF; Francis PA; Price KN; Coates AS; Gelber RD; Goldhirsch A; Walley BA
    Lancet Oncol; 2015 Jul; 16(7):848-58. PubMed ID: 26092816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival.
    Zhang Y; Ji Y; Li J; Lei L; Wu S; Zuo W; Jia X; Wang Y; Mo M; Zhang N; Shen Z; Wu J; Shao Z; Liu G
    Breast Cancer Res Treat; 2018 Apr; 168(3):679-686. PubMed ID: 29332135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.
    Mathew A; Davidson NE
    Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.
    Conte B; Poggio F; Del Mastro L
    Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor-Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors.
    Suh KJ; Kim SH; Lee KH; Kim TY; Kim YJ; Han SW; Kang E; Kim EK; Kim K; No JH; Han W; Noh DY; Lee M; Kim HS; Im SA; Kim JH
    Cancer Res Treat; 2017 Oct; 49(4):1153-1163. PubMed ID: 28253566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients.
    Del Mastro L; Rossi G; Lambertini M; Poggio F; Pronzato P
    Cancer Treat Rev; 2016 Jan; 42():18-23. PubMed ID: 26613834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
    Tan SH; Wolff AC
    Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial.
    Kim HA; Lee JW; Nam SJ; Park BW; Im SA; Lee ES; Jung YS; Yoon JH; Kang SS; Lee SJ; Park KH; Jeong J; Cho SH; Kim SY; Kim LS; Moon BI; Lee MH; Kim TH; Park C; Jung SH; Gwak G; Kim J; Kang SH; Jin YW; Kim HJ; Han SH; Han W; Hur MH; Noh WC;
    J Clin Oncol; 2020 Feb; 38(5):434-443. PubMed ID: 31518174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major depressive symptoms in breast cancer patients with ovarian function suppression: a cross-sectional study comparing ovarian ablation and gonadotropin-releasing hormone agonists.
    Jiang J; Xu J; Cai L; Man L; Niu L; Hu J; Sun T; Zheng X
    BMC Psychiatry; 2021 Dec; 21(1):624. PubMed ID: 34895183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.
    Saha P; Regan MM; Pagani O; Francis PA; Walley BA; Ribi K; Bernhard J; Luo W; Gómez HL; Burstein HJ; Parmar V; Torres R; Stewart J; Bellet M; Perelló A; Dane F; Moreira A; Vorobiof D; Nottage M; Price KN; Coates AS; Goldhirsch A; Gelber RD; Colleoni M; Fleming GF; ; ;
    J Clin Oncol; 2017 Sep; 35(27):3113-3122. PubMed ID: 28654365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast Cancer in China: A Randomized Clinical Trial.
    Zong X; Yu Y; Yang H; Chen W; Ding X; Liu S; Li X; Chen X; Jiang C; Xia X; Huang R; Zhu M; Hu J; Liang C
    JAMA Oncol; 2022 Feb; 8(2):252-258. PubMed ID: 34967844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of gonadotropin-releasing hormone agonists for ovarian function suppression in premenopausal patients with hormone receptor-positive breast cancer: a retrospective single-center real-world study.
    Chen Y; Zhang R; Yan Y; Li H; Song G
    Breast Cancer Res Treat; 2024 May; ():. PubMed ID: 38709374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen.
    Ruddy KJ; DeSantis SD; Barry W; Guo H; Block CC; Borges V; Winer EP; Partridge AH
    Clin Breast Cancer; 2014 Dec; 14(6):413-6. PubMed ID: 24970714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression.
    Yeo W; Ueno T; Lin CH; Liu Q; Lee KH; Leung R; Naito Y; Park YH; Im SA; Li H; Yap YS; Lu YS;
    Breast Cancer Res Treat; 2019 Oct; 177(3):549-559. PubMed ID: 31270763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical ovarian suppression for adjuvant treatment in hormone receptor positive breast cancer in premenopausal patients.
    Oseledchyk A; Gemignani ML; Zhou QC; Iasonos A; Elahjji R; Adamou Z; Feit N; Goldfarb SB; Long Roche K; Sonoda Y; Goldfrank DJ; Chi DS; Saban SS; Broach V; Abu-Rustum NR; Carter J; Leitao M; Zivanovic O
    Int J Gynecol Cancer; 2021 Feb; 31(2):222-231. PubMed ID: 33273020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.